Latest Research

How long did patients stay on the Juniper UK program and why did they stop?

Peer-reviewed research reveals patient adherence to Juniper’s digital weight loss program

Published in the Journal of Community Medicine & Public Health
Authored by
Dr Louis Talay
Dr Matthew Vickers
Last updated
27
March
,
2024
5 min read

Key takeaways

  • Juniper UK patients stayed on the programme, on average, for 183 days.
  • The most common reason for discontinuing was the cost of the program, followed by dissatisfaction with the results and intolerable side effects.

Juniper’s adherence rate

Previous real-world research suggested that patients on Juniper’s platform were more likely to lose weight than clinical trials using the same medication.

However, to gain a more accurate understanding of how effective Juniper’s digital weight loss program really is, it’s important to understand how long patients remained on it, and why they discontinued treatment.

A dedicated adherence study published in the Journal of Community Medicine & Public Health indicated that patients stayed on the Juniper programme, on average, for 6 months (183 days). The two most common reasons for discontinuing the program were program cost (38.7%) and dissatisfaction with results (16.8%).

Data was taken from self-directed, non-incentivised patients. Unlike clinical trials, in which participants don’t have to pay for treatment, this was a real-world study.

Understanding patient adherence

  • This is the first peer-reviewed study to measure the adherence rate of a UK digital weight loss service
  • The Juniper program is designed to give patients the tools they need to succeed, however, adherence to our recommended program is not mandatory
  • This study was entirely comprised of self-directed, non-incentivised patients
  • As stock availability of these treatments improves, patient adherence to Juniper’s comprehensive, multidisciplinary program should improve

Key reasons for discontinuation

  • Program cost (38.7%)
  • Dissatisfaction with results (16.8%)
  • Intolerable side effects (15.4%)
  • Goal achieved (7.3%)
  • Temporary hiatus/going on holiday (5.6%)

Why we did this research

In order to continue improving our program, we wanted to better understand exactly how long the average patient stayed on Juniper’s program and what barriers they experienced to continuing treatment.

We’re committed to transparently publishing our data so that we can continue to improve our program.

Medically reviewed by

Dr Louis Talay

Medical Research Lead | Eucalyptus

Dr Matthew Vickers

Clinical Director | Eucalyptus

Explore more research

Juniper AU
 •
Journal of Community Medicine & Public Health
 •
L. Talay
M. Vickers

How long did patients stay on the Juniper AU program and why did they stop?

June 6, 2024
Juniper AU
 •
Journal of Healthcare
 •
L. Talay
M. Vickers

A world-first study to report prescribing error rates in a real-world GLP-1 digital weight loss service

October 21, 2024